Elevated Matrix Metalloproteinase 9 in Treatment Resistant Bipolar Depression

Year 2023, , 434 - 440, 15.06.2023

Evangelia Fatourou Alexander Truong Debra Hoppensteadt Jawed Fareed Daniel Hain James Sinacore , Angelos Halaris

https://doi.org/10.33808/clinexphealthsci.1123325

Abstract

Objective: Matrix metalloproteinase is a family of proteases with different pathophysiological roles. Matrix metalloproteinase 9 (MMP9) plays an enzymatic role in the restructuring of the extracellular matrix and adhesion molecules. MMP9 is upregulated in pro-inflammatory states and leads to breakdown of tight junctions thereby increasing blood-brain barrier (BBB) permeability. MMP9 may contribute to the pathophysiology of bipolar disorder (BD) via proteolysis of the BBB thus allowing entry of cytokines and neurotoxic agents into CNS. Polymorphisms of the MMP9 gene may pose increased risk for BD and schizophrenia. In this study we sought to determine MMP9 levels in treatment resistant bipolar depressed patients before and after treatment.
Methods: Treatment resistant bipolar depressed patients were treated with escitalopram, in combination with the COX-2 inhibitor, celecoxib. It was hypothesized that combination treatment would reverse resistance and augmented treatment responses. This was a 10-week, randomized, double-blind, two-arm, placebo-controlled study.
Results: MMP9 levels were higher in bipolar depressed patients compared to healthy controls at baseline, however, the difference did not reach significance. Levels decreased after treatment reaching significance in the escitalopram plus placebo group. Female patients had significantly lower MMP9 levels at end of treatment. MMP9 was higher in carriers the MMP9 SNP, rs3918242, than in noncarriers, but the difference did not reach statistical significance.
Conclusion: MMP9 decreased in bipolar depressed patients with treatment. Age, sex and the rs3918242 polymorphism play a role in MMP9 levels. Future studies should confirm the role of MMP9 in the pathogenesis and pathophysiology of bipolar disorder, as a potential diagnostic biomarker.

Keywords

Bipolar depression, treatment resistance, MMP9, blood-brain barrier, inflammation, celecoxib

References

• Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol. 2014; 43(2): 476–493.
• Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Firmo JO, Castro-Costa E. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry 2015; 37(2):155-61.
• Gerber SI, Krienke UJ, Biedermann NC, Grunze H, Yolken RH, Dittmann S, Langosch JM. Impaired functioning in euthymic patients with bipolar disorder—HSV-1 as a predictor. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36(1):110-6.
• Johansson V, Kuja-Halkola R, Cannon TD, Hultman CM, Hedman AM. A population-based heritability estimate of bipolar disorder – In a Swedish twin sample. Psychiatry Res. 2019; 278:180-187.
• Han KM, De Berardis D, Fornaro M, Kim YK. Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Prog Neuropsychopharmacol. Biol. Psychiatry 2019; 91:20-27.
• Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol. 2006; 2:199-235.
• Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol. 2007; 10(4):547-55.
• Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V. Electron microscopy of oligodendroglia in severe mental illness. Brain Research Bulletin 2001; 55 (5):597-610.
• Heng S, Song AW. Sim K. White matter abnormalities in bipolar disorder: insights from diffusion tensor imaging studies. 2010. Journal of Neural Transmission 2010; 117(5):639–654.
• Patel JP, Frey BN. Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? Neural Plast. 2015; 2015:708306.
• Rybakowski JK. Matrix Metalloproteinase-9 (MMP9)—A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders. Cardiovasc Psychiatry Neurol. 2009; 2009: 904836.
• Greene C, Hanley N, Campbell M. Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. Transl Psychiatry 2020; 10(1):373.
• Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek, J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW. Matrix Metalloproteinase-9 Is Required for Hippocampal LatePhase Long-Term Potentiation and Memory. The Journal of Neuroscience 2006; 26 (7):1923-1934.
• Bobińska K, Szemraj J, Czarny P, Gałecki P. Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder. J Affect Disord. 2016; 205:119-129.
• Rybakowski JK, Skibinska M, Leszczynska-Rodziewicz A, Kaczmarek L, Hauser J. Matrix metalloproteinase-9 gene and bipolar mood disorder. Neuromolecular Med. 2009; 11(2):12832. [
• McGregor NW, Dimatelis JJ, Van Zyl PJ, Hemmings SMJ, Kinnear C, Russell VA, Stein DJ, Lochner C. A translational approach to the genetics of anxiety disorders. Behav Brain Res. 2018; 341:91-97.
• Reininghaus EZ, Lackner N, Birner A, Bengesser S, Fellendorf FT, Platzer M, Rieger A, Queissner R, Kainzbauer N, Reininghaus B, McIntyre RS, Mangge H, Zelzer S, Fuchs D, Dejonge S, Müller N. Extracellular matrix proteins matrix metallopeptidase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. Bipolar Disord. 2016; 18(2):155-63.
• Edberg D, Hoppensteadt D, Walborn A, Fareed J, Sinacore J, Halaris A. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2018; 102:1-7.
• Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One. 2010; 5(2): e9166.
• Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population. Psychosom Med. 2009; 71(3):292-300.